Mucopolysaccharidoses Stem Cell Therapy Development

Mucopolysaccharidoses (MPS) is a group of genetic disorders that affect the body's ability to break down and recycle complex sugars called mucopolysaccharides or glycosaminoglycans. CD BioSciences has launched a development service for mucopolysaccharidoses stem cell therapies, dedicated to advancing the treatment of this disease.

Introduction into Mucopolysaccharidoses

Mucopolysaccharidoses (MPS) are a group of inherited disorders that impair the body's capacity to break down and recycle intricate sugars, such as mucopolysaccharides or glycosaminoglycans. These sugars are essential components of many tissues, including bone, cartilage, tendons, skin, and connective tissue. Individuals with MPS are unable to break down these sugars due to a deficiency in one of several enzymes required for the process. As a result, the mucopolysaccharides accumulate in various tissues and organs, leading to a wide range of symptoms and medical problems.

The pathogenetic cascade of mucopolysaccharidoses (Fecarotta, Simona et al., 2020)

The severity of MPS can vary greatly depending on the specific type and the amount of accumulated mucopolysaccharides. Symptoms may include skeletal abnormalities, joint stiffness, enlarged organs, vision and hearing problems, breathing difficulties, and cognitive impairment. Some forms of MPS can also lead to life-threatening complications.

Stem Cell Therapy for Mucopolysaccharidoses

Stem cell therapy is a promising treatment approach for Mucopolysaccharidoses (MPS). Stem cells are unique cells that have the ability to develop into many different types of cells in the body. In the case of MPS, stem cells can be used to replace or repair damaged cells that are responsible for producing the deficient enzyme.

Process by which HSCT treats patients with MPS (Taylor, Madeleine et al., 2019)

There are several types of stem cell therapies being investigated for the treatment of Mucopolysaccharidoses. Here are a few examples:

• Hematopoietic stem cell (HSC) transplantation: In this approach, HSCs are taken from the patient or a donor and modified to produce the missing enzyme. The modified stem cells are then infused back into the patient where they can migrate to the affected tissues and organs and produce the enzyme.
• Umbilical cord blood transplantation: Stem cells from umbilical cord blood can also be used for transplantation in MPS patients. Cord blood is rich in HSCs and is collected from the umbilical cord shortly after birth.
• Mesenchymal stem cell (MSC) therapy: MSCs are a type of stem cell that can differentiate into several types of cells, including bone, cartilage, and fat cells. In MPS, MSCs can be used to replace damaged or missing cells in affected tissues and organs.

Our Services

CD BioSciences offers mucopolysaccharidoses stem cell therapy development services. Based on our professional team and advanced technology, we can contribute to the development of stem cell therapy for mucopolysaccharidoses. As a trustable CRO company, CD BioSciences offers stem cell therapy development services for mucopolysaccharidoses.

Workflow of our services

Stem Cell Isolation

Stem Cell Culturing

Stem Cell Engineering

Stem Cell Differentiation

Stem Cell Characterization

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

References

1. Fecarotta, Simona et al. (2020). Pathogenesis of Mucopolysaccharidoses, an Update. International journal of molecular sciences vol. 21,7 2515. 4 Apr. 2020.
2. Taylor, Madeleine et al. (2019) "Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation vol. 25,7: e226-e246.